Peer-reviewed veterinary case report
Lomustine chemo shows 25% response in cats with vaccine sarcoma
By Saba, C F et al.·Published in Veterinary and comparative oncology·2012·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma.
- Species:
- cat
Plain-English summary
A group of 28 cats with vaccine-associated sarcoma (a type of cancer that can occur after vaccination) were treated with a chemotherapy drug called lomustine. While the treatment showed some promise, with 25% of the cats responding positively, the average time before the cancer progressed was about 60 days. However, many cats experienced significant side effects, like low white blood cell counts, which led to dose adjustments and delays in treatment. More research is needed to find safer ways to use lomustine for these cats.
People also search for: cat vaccine-associated sarcoma treatment · lomustine for cats cancer · feline chemotherapy side effects
Abstract
Treatment of feline vaccine-associated sarcoma (VAS) is challenging, in part due to the high likelihood of tumour recurrence despite aggressive local therapy. Lomustine is potentially an attractive agent to add to the current treatment armamentarium. In this de-escalating phase I/II prospective trial, 28 cats with measurable VAS were treated at target dosages of 38-60 mg m(-2) every 3 weeks until disease progression. The overall response rate was 25%, with a median progression-free survival and median duration of response of 60.5 and 82.5 days, respectively. Haematologic toxicity, specifically cumulative neutropenia, was significant, and dose reductions and treatment delays were common. Although these data support further investigation of lomustine for the treatment of VAS, safe, multidosing protocols must first be determined.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22236148/